•
Dec 31, 2023

Glaukos Q4 2023 Earnings Report

Glaukos's Q4 2023 earnings were announced, featuring record net sales and advancements in their pipeline.

Key Takeaways

Glaukos Corporation reported record net sales of $82.4 million for Q4 2023, a 16% increase year-over-year. The company reaffirmed its 2024 net sales guidance of $350 million to $360 million.

Record net sales of $82.4 million in Q4 2023, up 16% year-over-year.

Glaucoma net sales reached $60.6 million, a 15% increase year-over-year.

Corneal Health net sales were $21.8 million, reflecting a 19% year-over-year growth.

Gross margin was approximately 77%, with a non-GAAP gross margin of about 84%.

Total Revenue
$82.4M
Previous year: $71.2M
+15.6%
EPS
-$0.63
Previous year: -$0.53
+18.9%
Gross margin
77%
Previous year: 76%
+1.3%
Non-GAAP gross margin
84%
Previous year: 84%
+0.0%
SG&A expenses
$63M
Previous year: $51.9M
+21.4%
Gross Profit
$63.5M
Previous year: $54M
+17.5%
Cash and Equivalents
$93.5M
Previous year: $120M
-21.8%
Free Cash Flow
-$14.9M
Previous year: -$12.4M
+20.4%
Total Assets
$940M
Previous year: $1B
-6.2%

Glaukos

Glaukos

Glaukos Revenue by Segment

Forward Guidance

The company expects 2024 net sales to be in the range of $350 million to $360 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income